

Chapter 07 / Capítulo 07

Advanced Prostate Adenocarcinoma and Androgen Deprivation Therapy. Clinical Outcomes, Risk Stratification, and Therapeutic Results

ISBN: 978-9915-9869-7-5

DOI: 10.62486/978-9915-9869-7-5.Ch07

Pages: 54-60

©2024 The authors. This is an open access book distributed under the terms of the Creative Commons Attribution (CC BY) 4.0 License.

Operational recommendations and areas for improvement

A comprehensive review of the results presented throughout this book allows us to outline a map of clinical and organizational priorities for the management of advanced prostate adenocarcinoma under total androgen deprivation. The predominant profile of the cohort—older patients with a high-risk classification—is not an incidental detail: it guides the direction of each therapeutic decision and determines the type of follow-up that is reasonable, realistic, and ethically consistent. When the disease is diagnosed at an advanced stage, the horizon of clinical care shifts. The goals are not only expressed in terms of tumor control but also in terms of functional preservation, symptomatic relief, maintenance of autonomy, reduction in complications, and sustained support for the patient and their environment.

In this scenario, the operational question is not usually “what treatment is available,” but “what treatment is appropriate here, for this patient, with this risk, with this history, with this family support, and with this health system.” The decision requires weighing efficacy, tolerance, accessibility, continuity, and follow-up capacity. Total androgen deprivation occupies a central place because its impact on symptom control is tangible and because its biological rationale is consistent. Even so, hormone treatment is not a single act; it is a process. A process that needs clear rules, defined timelines, well-interpreted markers, and an honest clinical conversation about the expectations and human costs of treatment.

This chapter proposes operational recommendations and areas for improvement organized around five axes: (1) therapeutic selection and follow-up planning, (2) monitoring of progression and detection of hormone resistance, (3) adherence and therapeutic continuity, (4) comprehensive management of adverse effects with an emphasis on sexual function and quality of life, and (5) strengthening of clinical records and institutional coordination. The objective is not to establish a uniform prescription but rather to offer a replicable framework that allows for improved clinical consistency, reduced avoidable variability, and a more predictable institutional response to complex trajectories.

Therapeutic selection in advanced disease: practical criteria and clinical realism

When the diagnosis is established with advanced disease and high risk, therapeutic selection should avoid two extremes: inertia (maintaining the same regimen without periodic reevaluation) and impulsive change (modifying treatments without defined criteria). Total androgen deprivation, owing to its symptomatic control profile, can be sustained as a baseline treatment but requires an explicit follow-up plan. This plan should include what is monitored, how often, what thresholds trigger a reassessment, and what alternatives are considered if progression occurs.

Operational recommendations

- At the start of treatment, a written “follow-up itinerary” is defined in the medical records: frequency of consultations, tentative dates for biochemical measurements, symptom assessments, and monitoring of adverse events.
- Establish a scheduled (nonreactive) clinical reassessment point: a specific consultation to review biochemical response, functional status, symptoms, tolerance, and adherence.
- The objectives are differentiated on two levels: oncological objective (control of tumor activity and signs of progression) and well-being objective (symptoms, sleep,

energy, mood, sexuality, pain).

This approach prevents hormone therapy from becoming a repetitive practice. In older patients, therapeutic continuity is maintained when the patient understands the purpose of the treatment, recognizes what effects are to be expected, and perceives that there is a team attentive to their experience. Clinical trust is often a silent factor that sustains adherence, particularly when treatment changes intimate aspects of daily life.

Progression monitoring: integrated PSA, testosterone, and clinical readings

Progression in advanced prostate cancer does not always manifest in the same way. It can present as elevated markers, clinical changes, new images consistent with active disease, or a combination of these elements. This study revealed a guiding sequence: elevated PSA appears more frequently in the intermediate stages of follow-up, and elevated testosterone becomes more relevant in later stages, becoming a critical indicator in the recognition of hormonal escape. This observation can be translated into practical rules for monitoring.

The central recommendation is to abandon the isolated reading of markers. A rising PSA does not have the same meaning if testosterone is suppressed or if it has recovered to normal levels; similarly, rising testosterone raises questions about the actual effectiveness of the blockade, the regularity of treatment and factors that may explain loss of suppression.

Operational recommendations

- PSA and testosterone should be monitored in a coordinated manner, with a joint interpretation documented in the medical records.
- Define internal (operational) alert thresholds that require reassessment, even if behavior is not immediately modified. The value of a threshold lies not only in the number but also in the discipline of reviewing the patient when that limit is crossed.
- A structured clinical evaluation should be incorporated into each check-up to assess the following parameters: bone pain, urinary changes, weight loss, persistent fatigue, compressive symptoms, signs of obstruction, and recent functional alterations.

Areas for improvement

- A standard follow-up sheet that includes date, PSA, testosterone, main symptoms, and clinical decisions was designed. A simple tool reduces omissions and improves continuity between different professionals.
- Establish a pathway for “suspected hormone resistance”: biochemical confirmation, adherence review, androgen suppression verification, disease extension assessment, and therapeutic discussion.

This point is essential: hormonal escape should not be detected late. Early detection does not imply alarmism; it implies preparation. A system that anticipates scenarios reduces improvisation and better protects the patient.

Therapeutic adherence: understanding discontinuation as a clinical sign

During the observation period, adherence remained predominant, but there was a phase with an increase in nonadherence. In a book geared toward clinical practice, this finding should be read as a signal: adherence is not a fixed attribute of the patient; it is a relationship. When it fails, it rarely fails for a single reason.

Noncompliance can result from barriers to access, treatment fatigue, cumulative adverse effects, loss of confidence, denial, logistical difficulties, depressive symptoms, or lack of family support. If it is approached with a punitive approach (“the patient is not complying”), the likelihood of regaining continuity decreases. If it is approached as clinical data (“something is interfering”), the conversation changes.

Operational recommendations

- A brief adherence check at each consultation was performed, with simple, nonaccusatory questions concerning the following: actual frequency of administration, interruptions, difficulties, and adverse events that led to discontinuation.
- Document the probable cause of nonadherence when identified: adverse effects, access, forgetfulness, lack of understanding, personal conflicts, and emotional fragility.
- A standardized minimum intervention for nonadherence should be established: brief education, adjustment of adverse effect management, coordination with pharmacies/services, and early rescheduling of follow-up.

Areas for improvement

- Create an institutional support channel for therapeutic continuity: telephone coordination or brief consultation for patients who interrupt treatment or miss follow-up appointments.
- Identifying “critical points” of adherence, for example, periods when hot flashes, sexual dysfunction, fatigue, or mood swings tend to occur. If adverse effects are anticipated, the likelihood of silent abandonment is reduced.

In older patients, adherence is also supported by structure: reminders, family support, clear instructions, and closer follow-up when there are signs of frailty.

Adverse effects and daily life: placing sexual function at the center of care

This study revealed that erectile function was the main area affected after the start of hormone treatment. This finding deserves careful consideration, not as a side note but as a central part of medicine that recognizes the whole person.

Sexual dysfunction is not just an “expected” consequence of physiology; it can affect self-esteem, relationships, personal identity, intimacy, and emotional well-being. In cultural contexts where male sexuality is associated with ideas of vigor or social role, the impact can be even more profound. In the clinical setting, there is a risk of minimizing it out of modesty, lack of time, or the belief that “it does not matter in older patients.” This risk impoverishes care and erodes trust.

Operational recommendations

- Explicitly open the conversation about sexuality before initiating androgen deprivation: Inform the patient about what to expect, ask about concerns, and record the patient’s priorities.
- Sexual symptoms were assessed as part of follow-up, not just as an adverse event: desire, erection, satisfaction, physical discomfort, and changes in relationships.
- Offer alternative approaches as available: counseling, psychological support, education for the partner, pharmacological interventions when appropriate, and referral to sexology or functional urology if resources are available.

The goal is not always to “restore” function but rather to preserve dignity, reduce avoidable suffering, and sustain relationships. A well-conducted conversation does not create problems; it names what is already happening and allows the patient to feel supported.

Other reported adverse effects include vasomotor symptoms, gynecomastia, mastodynia, bone pain, and less frequent events with clinical relevance, such as hepatotoxicity. Each requires a specific response.

Operational recommendations

- Flashes/heat waves: The symptoms should be validated, their impact on sleep and quality of life should be quantified, and management measures should be proposed according to guidelines and resources.
- Gynecomastia and mastodynia: explain the mechanism, offer relief strategies, and assess the emotional impact.
- Bone pain: Bone pain can be differentiated into pain due to metastasis, bone fragility, or other causes, and evaluation can be coordinated with stepwise analgesia.
- Hepatotoxicity: Laboratory monitoring when justified by the pharmacological regimen and clear record of conduct in case of alteration.

Areas for improvement

- Incorporate a “minimum therapeutic education package” at the outset: a simple sheet with expected effects, warning signs, and contacts.
- Periodic quality-of-life assessment should be implemented with brief instruments, especially in patients with signs of depression, severe fatigue, or isolation.

Quality of life is not an abstract concept. It is measured in nights of sleep, in the ability to walk without pain, in the face of treatment, in the continuity of personal projects, and in sustained relationships.

Metastatic lesions and bone care: follow-up, prevention, and continuity

Bone metastases are among the most frequent manifestations of progression. Bone care is not an appendage to oncological management: it is a dimension of skeletal event prevention, pain control, mobility preservation, and autonomy protection.

The use of zoledronic acid and gamma ray monitoring, which has improved in some patients, suggests that the bone support strategy has an impact and should be more clearly integrated into the clinical pathway. The recommendation is to build a bone care pathway with three components: detection, intervention, and follow-up.

Operational recommendations

- To establish criteria for evaluating bone spread in patients with signs of progression, persistent pain, or significant biochemical elevation.
- Guidelines for monitoring pain and motor function should be defined as part of regular check-ups.
- The bone support treatment cycles were recorded, continuity was ensured, and the reasons for interruption (adverse effects, access, treatment fatigue) were identified.

Areas for improvement

- Coordination between urology, oncology, imaging, laboratory, and pain/palliative

care should be created when available, with clear referral pathways.

- Patient education on risk signs should be provided: new persistent pain, falls, sudden loss of strength, and neurological symptoms.

Preventing bone events not only reduces suffering but also reduces avoidable hospitalizations and protects clinical resources.

Clinical records and institutional intelligence: Standardizing to provide better care

One of the most impactful improvements is often the simplest: standardize record keeping. When follow-up depends on inconsistent notes, data are lost, decisions are repeated, detection of progression is delayed, and care is fragmented. This book already includes a data collection form/tool; that tool can evolve into a clinical care format.

Operational recommendations

- A standard control sheet for each consultation was designed: PSA, testosterone, key symptoms, adverse effects, adherence, clinical decisions, and planning for the next evaluation.
- Minimum mandatory fields should be incorporated: risk classification, stage, hormone regimen, start date, and reason for changes.
- Explicitly recording the interpretation of markers is not enough to note values; it must be clear what they mean for the team.

Areas for improvement

- An institutional basis for advanced cases should be established, with periodic review of indicators such as percentage with bone progression, frequency of hormone resistance, therapeutic continuity, and major adverse events.
- Brief clinical audits of patients with rapid progression or therapeutic interruption should be performed with a formative, not punitive, approach.

Institutional intelligence does not replace clinical intelligence; it supports it. A team that learns from its own data has an improved ability to anticipate and reduce avoidable variability.

Interpretative limitations and scope of applied research

The study is based on a descriptive cross-sectional observational design in a specific healthcare setting. This framework adds value owing to its proximity to real practice, but it also limits the type of statements that can be made. The interpretation does not attempt to establish causality or automatically generalize to other contexts. The value lies in describing trajectories and patterns that, within this institutional setting, guide clinical decisions and raise questions.

In terms of future development, there are lines of applied research that can strengthen the understanding of the phenomenon and improve care: longitudinal studies with longer follow-up, incorporation of standardized quality of life instruments, analysis of factors associated with nonadherence, and comparative evaluation of therapeutic regimens according to risk and comorbidity profiles. It is also important to delve deeper into qualitative dimensions: how patients experience hormone treatment, what barriers they perceive, what expectations they have, and what fears condition their therapeutic continuity.

Closing the chapter: more predictable, humane, and consistent clinical practice

The recommendations made in this chapter are based on a simple idea: advanced disease requires care that is not improvised. Total androgen deprivation allows symptomatic control and provides a solid therapeutic framework, but its clinical effectiveness depends on integrated monitoring, therapeutic continuity, real attention to adverse effects, and an institutional culture that records, reviews, and acts.

The predominance of older, high-risk patients reminds us that care must be proportional to the frailty and human impact of treatment. Detecting hormone resistance requires clinical discipline: PSA and testosterone are read together, with thresholds for reassessment and clear response pathways. Adherence should be treated as clinical data that invites understanding, not as a judgment. The sexual sphere should no longer be a taboo topic: its impact affects quality of life and psychological well-being.

If the system manages to integrate these elements—planned follow-up, coordinated reading of markers, structured management of adverse effects, bone care, and standardized recording—treatment ceases to be a set of isolated acts and becomes a coherent clinical process. This process not only improves care but also builds trust and dignity in scenarios where uncertainty often accompanies the patient from diagnosis onward.